A case of abatacept associated neutrophilic dermatosis and a review of the literature

S.M. Tiwari, Benjamin Wood, T.M. Skender-Kalnenas, N. Cook

    Research output: Contribution to journalReview article

    8 Citations (Scopus)

    Abstract

    Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept. © 2014 The Australasian College of Dermatologists.
    Original languageEnglish
    Pages (from-to)214-217
    JournalAustralasian Journal of Dermatology
    Volume55
    Issue number3
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Skin Diseases
    T-Lymphocytes
    Biological Factors
    Biological Products
    Rheumatoid Arthritis
    Down-Regulation
    Tumor Necrosis Factor-alpha
    Safety
    Skin
    Abatacept
    Therapeutics

    Cite this

    Tiwari, S.M. ; Wood, Benjamin ; Skender-Kalnenas, T.M. ; Cook, N. / A case of abatacept associated neutrophilic dermatosis and a review of the literature. In: Australasian Journal of Dermatology. 2014 ; Vol. 55, No. 3. pp. 214-217.
    @article{36c0ee89def54ed680fb45e3e0e96609,
    title = "A case of abatacept associated neutrophilic dermatosis and a review of the literature",
    abstract = "Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept. {\circledC} 2014 The Australasian College of Dermatologists.",
    author = "S.M. Tiwari and Benjamin Wood and T.M. Skender-Kalnenas and N. Cook",
    year = "2014",
    doi = "10.1111/ajd.12185",
    language = "English",
    volume = "55",
    pages = "214--217",
    journal = "Australian Journal of Dermatology",
    issn = "0004-8380",
    publisher = "John Wiley & Sons",
    number = "3",

    }

    A case of abatacept associated neutrophilic dermatosis and a review of the literature. / Tiwari, S.M.; Wood, Benjamin; Skender-Kalnenas, T.M.; Cook, N.

    In: Australasian Journal of Dermatology, Vol. 55, No. 3, 2014, p. 214-217.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - A case of abatacept associated neutrophilic dermatosis and a review of the literature

    AU - Tiwari, S.M.

    AU - Wood, Benjamin

    AU - Skender-Kalnenas, T.M.

    AU - Cook, N.

    PY - 2014

    Y1 - 2014

    N2 - Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept. © 2014 The Australasian College of Dermatologists.

    AB - Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept. © 2014 The Australasian College of Dermatologists.

    U2 - 10.1111/ajd.12185

    DO - 10.1111/ajd.12185

    M3 - Review article

    VL - 55

    SP - 214

    EP - 217

    JO - Australian Journal of Dermatology

    JF - Australian Journal of Dermatology

    SN - 0004-8380

    IS - 3

    ER -